11.3 Smoking Cessation & Lifestyle Medicine

Smoking Cessation & Lifestyle Medicine

Chronic non-communicable diseases—including cardiovascular disease, type 2 diabetes, and chronic obstructive pulmonary disease—are the leading causes of morbidity and mortality globally. Primary care physicians play a pivotal role in mitigating these risks through targeted lifestyle interventions, including smoking cessation counseling, pharmacotherapy, nutrition guidance, and physical activity prescription.

Smoking Cessation Counseling: The 5 A's Framework

The 5 A's framework is an evidence-based tool designed to guide clinicians through a structured, brief smoking cessation intervention during routine consultations:

1. Ask: Systematically identify and document the tobacco use status of every patient at every visit. Ask about the type of tobacco (e.g., cigarettes, shisha, e-cigarettes) and the frequency of use.
2. Advise: Urge every tobacco user to quit in a clear, strong, and personalized manner. Connect the advice to the patient's current health status, family situation, or financial costs (e.g., "Quitting smoking is the single most important action you can take to protect your lungs and reduce the frequency of your asthma attacks").
3. Assess: Determine the patient's readiness to make a quit attempt within the next 30 days.
   • If the patient is ready to quit, proceed to Assist.
   • If the patient is not ready to quit, provide a motivational intervention built around the 5 R's (Relevance, Risks, Rewards, Roadblocks, Repetition).
4. Assist: Help the patient develop a quit plan. This includes setting a quit date (ideally within 2 weeks), identifying triggers, advising them to remove tobacco products from their environment, and offering pharmacotherapy.
5. Arrange: Schedule follow-up contact (in person or via phone), ideally within the first week after the quit date. A second follow-up is recommended within the first month.

---

Smoking Cessation Pharmacotherapy

First-line pharmacotherapy should be offered to all dependent smokers who are motivated to quit, unless contraindicated. Combining behavioral counseling with pharmacotherapy significantly increases long-term abstinence rates compared to either intervention alone.

1. Nicotine Replacement Therapy (NRT)

NRT delivers nicotine to reduce withdrawal symptoms and cravings without the toxic carcinogens present in tobacco smoke.

• Long-acting NRT: The transdermal nicotine patch provides a steady, continuous level of nicotine over 16 or 24 hours.
• Short-acting NRT: Nicotine gum, lozenges, inhalers, and nasal sprays provide rapid relief for acute cravings.
• Clinical Pearl: Combination NRT (using a patch for baseline control plus gum or lozenge for breakthrough cravings) is significantly more effective than monotherapy and should be considered first-line.

2. Varenicline

• Mechanism: A selective $\alpha_4\beta_2$ nicotinic acetylcholine receptor partial agonist. It stimulates low-level dopamine release to reduce withdrawal symptoms (agonist effect) while blocking inhaled nicotine from binding to the receptor, thereby reducing the reinforcing reward of smoking (antagonist effect).
• Efficacy: Varenicline has the highest monotherapy success rate, superior to both bupropion and nicotine patch monotherapy.
• Administration: Start varenicline 1 to 2 weeks before the chosen quit date. Titrate the dose over a week to minimize adverse effects. The standard course is 12 weeks, which can be extended for another 12 weeks to prevent relapse.
• Adverse Effects: Nausea (most common, mitigated by taking with food and a full glass of water), insomnia, and vivid or abnormal dreams. Monitor for neuropsychiatric symptoms (mood changes, suicidal ideation), although recent large trials (EAGLES) show no significant increase in neuropsychiatric risks compared to placebo.

3. Bupropion (Sustained-Release)

• Mechanism: A weak inhibitor of neuronal reuptake of dopamine and norepinephrine, which helps attenuate withdrawal symptoms and cravings.
• Efficacy: Comparable to nicotine patch monotherapy.
• Administration: Start bupropion 1 to 2 weeks before the quit date. The standard treatment duration is 7 to 12 weeks.
• Contraindications:
  • Seizure disorders (bupropion lowers the seizure threshold).
  • Current or prior diagnosis of anorexia nervosa or bulimia (associated with a higher incidence of seizures when taking bupropion).
  • Abrupt withdrawal from alcohol, benzodiazepines, or sedatives.
  • Use of Monoamine Oxidase Inhibitors (MAOIs) within the preceding 14 days.

---

Exercise Promotion & Prescription

Physical inactivity is a major risk factor for cardiovascular disease. The GP should prescribe exercise with the same specificity as pharmacotherapy, using the FITT principle (Frequency, Intensity, Time, Type).

Physical Activity Guidelines for Adults (Aged 18–64 years):

• Aerobic Exercise:
  • At least 150 minutes of moderate-intensity aerobic physical activity per week (e.g., brisk walking, water aerobics, cycling $<16$ km/h), OR
  • At least 75 minutes of vigorous-intensity aerobic physical activity per week (e.g., running, swimming laps, singles tennis), OR
  • An equivalent combination of moderate- and vigorous-intensity activity.
• Muscle-Strengthening Activities:
  • Moderate- or high-intensity strength training involving all major muscle groups on 2 or more days per week.
• Health Benefits: Meeting these targets reduces the risk of all-cause mortality, coronary heart disease, stroke, hypertension, type 2 diabetes, metabolic syndrome, and colon/breast cancers.

---

Nutritional Guidance

A primary care approach to nutrition focuses on long-term dietary patterns rather than short-term restrictive dieting.

Key Dietary Patterns & Guidelines:

1. The Mediterranean Diet: Emphasizes high consumption of vegetables, fruits, whole grains, beans, nuts, and seeds; olive oil as the primary source of fat; moderate intake of fish, poultry, and dairy; and low intake of red meat and sweets. This pattern is strongly associated with a reduction in cardiovascular events and improvement in insulin sensitivity.
2. Saturated & Trans Fats: Saturated fat intake should be limited to $<10%$ of total daily energy intake ($<7%$ for patients with hypercholesterolemia). Trans fats should be completely avoided.
3. Dietary Fiber: A daily fiber intake of 25 to 30 grams from whole foods is recommended to support glycemic control and lipid clearance.
4. Sodium Restriction:

• General population: Limit sodium intake to $<2,300$ mg/day (equivalent to approximately 1 teaspoon of table salt).
• Hypertensive, diabetic, or chronic kidney disease patients: Limit sodium intake to $<1,500$ mg/day to optimize blood pressure control.